{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:12:28Z","timestamp":1790770348375,"version":"4.1.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["WO2018231974A1"],"award-info":[{"award-number":["WO2018231974A1"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008513","name":"Thomas Jefferson University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 AI128175"],"award-info":[{"award-number":["R21 AI128175"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.celrep.2020.107920","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T10:39:15Z","timestamp":1595327955000},"page":"107920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9308-9873","authenticated-orcid":false,"given":"Christine R.","family":"Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4953-1780","authenticated-orcid":false,"given":"David E.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd G.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina L.","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wirblich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9206-9640","authenticated-orcid":false,"given":"Gino","family":"Cingolani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias J.","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2020.107920_bib1","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever","volume":"9","author":"Abreu-Mota","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2020.107920_bib2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3201\/eid1905.121071","article-title":"Novel lyssavirus in bat, Spain","volume":"19","author":"Ar\u00e9chiga Ceballos","year":"2013","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.celrep.2020.107920_bib3","doi-asserted-by":"crossref","first-page":"8096","DOI":"10.1128\/JVI.75.17.8096-8104.2001","article-title":"Host switching in Lyssavirus history from the Chiroptera to the Carnivora orders","volume":"75","author":"Badrane","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib4","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1128\/JVI.75.7.3268-3276.2001","article-title":"Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity","volume":"75","author":"Badrane","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0264-410X(97)00204-1","article-title":"DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses","volume":"16","author":"Bahloul","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2020.107920_bib6","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.3390\/v6082974","article-title":"Lyssaviruses and bats: emergence and zoonotic threat","volume":"6","author":"Banyard","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.celrep.2020.107920_bib7","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1128\/jvi.65.8.4198-4203.1991","article-title":"Antigenicity of rabies virus glycoprotein","volume":"65","author":"Benmansour","year":"1991","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib8","doi-asserted-by":"crossref","first-page":"10605","DOI":"10.1128\/JVI.00558-11","article-title":"Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses","volume":"85","author":"Blaney","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib9","doi-asserted-by":"crossref","first-page":"e1003389","DOI":"10.1371\/journal.ppat.1003389","article-title":"Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine","volume":"9","author":"Blaney","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.celrep.2020.107920_bib10","doi-asserted-by":"crossref","first-page":"e01546-17","DOI":"10.1128\/JVI.01546-17","article-title":"Structural Basis for Escape of Human Astrovirus from Antibody Neutralization: Broad Implications for Rational Vaccine Design","volume":"92","author":"Bogdanoff","year":"2017","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib11","series-title":"Joint WHO\/IABS Symposium on the Standardization of Rabies Vaccines for Human Use Produced in Tissue Culture [Rabies III]","first-page":"267","article-title":"Proposed International Reference Rabies Vaccine (HDC-Origin) and the potency tests used to test these products","author":"Bogel","year":"1978"},{"key":"10.1016\/j.celrep.2020.107920_bib12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(11)70340-1","article-title":"Passive immunity in the prevention of rabies","volume":"12","author":"Both","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.celrep.2020.107920_bib13","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1096\/fj.12-219964","article-title":"Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans","volume":"27","author":"Both","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.celrep.2020.107920_bib14","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.micinf.2010.06.005","article-title":"Fine mapping and interaction analysis of a linear rabies virus neutralizing epitope","volume":"12","author":"Cai","year":"2010","journal-title":"Microbes Infect."},{"key":"10.1016\/j.celrep.2020.107920_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12917-017-0948-0","article-title":"New isolations of the rabies-related Mokola virus from South Africa","volume":"13","author":"Coertse","year":"2017","journal-title":"BMC Vet. Res."},{"key":"10.1016\/j.celrep.2020.107920_bib16","doi-asserted-by":"crossref","first-page":"e13677","DOI":"10.1371\/journal.pone.0013677","article-title":"A synthetic adjuvant to enhance and expand immune responses to influenza vaccines","volume":"5","author":"Coler","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.celrep.2020.107920_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid1601.081467","article-title":"Public health threat of new, reemerging, and neglected zoonoses in the industrialized world","volume":"16","author":"Cutler","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.celrep.2020.107920_bib18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.15252\/emmm.201505986","article-title":"Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis","volume":"8","author":"De Benedictis","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.celrep.2020.107920_bib19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1073\/pnas.80.1.70","article-title":"Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus","volume":"80","author":"Dietzschold","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"Suppl 4","key":"10.1016\/j.celrep.2020.107920_bib20","doi-asserted-by":"crossref","first-page":"S785","DOI":"10.1093\/clinids\/10.Supplement_4.S785","article-title":"Antigenic diversity of the glycoprotein and nucleocapsid proteins of rabies and rabies-related viruses: implications for epidemiology and control of rabies","volume":"10","author":"Dietzschold","year":"1988","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.celrep.2020.107920_bib21","doi-asserted-by":"crossref","first-page":"7447","DOI":"10.1016\/j.vaccine.2012.10.015","article-title":"Rabies virus vaccines: is there a need for a pan-lyssavirus vaccine?","volume":"30","author":"Evans","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2020.107920_bib22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1099\/jgv.0.000998","article-title":"Antigenic site changes in the rabies virus glycoprotein dictates functionality and neutralizing capability against divergent lyssaviruses","volume":"99","author":"Evans","year":"2018","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/v10030130","article-title":"Utilisation of chimeric lyssaviruses to assess vaccine protection against highly divergent lyssaviruses","volume":"10","author":"Evans","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.celrep.2020.107920_bib24","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1007\/s00705-016-2982-9","article-title":"Livestock rabies outbreaks in Shanxi province, China","volume":"161","author":"Feng","year":"2016","journal-title":"Arch. Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib25","doi-asserted-by":"crossref","first-page":"1674580","DOI":"10.1155\/2016\/1674580","article-title":"Predicted 3D model of the rabies virus glycoprotein trimer","volume":"2016","author":"Fernando","year":"2016","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.celrep.2020.107920_bib26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrmicro.2018.11","article-title":"The spread and evolution of rabies virus: conquering new frontiers","volume":"16","author":"Fisher","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.celrep.2020.107920_bib27","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(13)62707-5","article-title":"Current status of rabies and prospects for elimination","volume":"384","author":"Fooks","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.celrep.2020.107920_bib28","doi-asserted-by":"crossref","first-page":"17091","DOI":"10.1038\/nrdp.2017.91","article-title":"Rabies","volume":"3","author":"Fooks","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.celrep.2020.107920_bib29","series-title":"06a\u2014Annex C: Rabies Investment Case: Vaccine Investment Strategy Programme and Policy Committee Meeting","year":"2018"},{"key":"10.1016\/j.celrep.2020.107920_bib30","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1128\/JVI.01870-09","article-title":"Characterization of a single-cycle rabies virus-based vaccine vector","volume":"84","author":"Gomme","year":"2010","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib31","doi-asserted-by":"crossref","first-page":"e0003709","DOI":"10.1371\/journal.pntd.0003709","article-title":"Estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.celrep.2020.107920_bib32","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1016\/S0264-410X(01)00135-9","article-title":"Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis","volume":"19","author":"Hanlon","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2020.107920_bib33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.virusres.2005.03.009","article-title":"Efficacy of rabies biologics against new lyssaviruses from Eurasia","volume":"111","author":"Hanlon","year":"2005","journal-title":"Virus Res."},{"key":"10.1016\/j.celrep.2020.107920_bib34","doi-asserted-by":"crossref","first-page":"11841","DOI":"10.1128\/JVI.01153-10","article-title":"Quantifying antigenic relationships among the lyssaviruses","volume":"84","author":"Horton","year":"2010","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib35","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1099\/vir.0.061952-0","article-title":"Antigenic and genetic characterization of a divergent African virus, Ikoma lyssavirus","volume":"95","author":"Horton","year":"2014","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib36","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3201\/eid2404.171696","article-title":"Lyssavirus in Japanese Pipistrelle, Taiwan","volume":"24","author":"Hu","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.celrep.2020.107920_bib37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1128\/JVI.73.1.225-233.1999","article-title":"Chimeric lyssavirus glycoproteins with increased immunological potential","volume":"73","author":"Jallet","year":"1999","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib38","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1099\/0022-1317-83-11-2663","article-title":"Canine vaccine recipients recognize an immunodominant region of the rabies virus glycoprotein","volume":"83","author":"Johnson","year":"2002","journal-title":"J.\u00a0Gen. Virol."},{"issue":"Suppl 3","key":"10.1016\/j.celrep.2020.107920_bib39","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1093\/infdis\/jiw231","article-title":"An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models","volume":"214","author":"Johnson","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.celrep.2020.107920_bib40","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1016\/j.vaccine.2010.08.082","article-title":"Rabies vaccines: WHO position paper\u2014recommendations","volume":"28","author":"Keates","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2020.107920_bib41","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nprot.2015.053","article-title":"The Phyre2 web portal for protein modeling, prediction and analysis","volume":"10","author":"Kelley","year":"2015","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.celrep.2020.107920_bib42","doi-asserted-by":"crossref","first-page":"e01865-18","DOI":"10.1128\/JVI.01865-18","article-title":"A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent Upon Antibody-Mediated Cellular Cytotoxicity for Protection Against Marburg Virus Disease in a Murine Model","volume":"93","author":"Keshwara","year":"2019","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib43","first-page":"37","article-title":"Pathogenicity and Immunogenicity of Recombinant Rabies Viruses Expressing the Lagos Bat Virus Matrix and Glycoprotein: Perspectives for a Pan-Lyssavirus Vaccine","volume":"2","author":"Kgaladi","year":"2017","journal-title":"Trop. Med. Infect. Dis."},{"key":"10.1016\/j.celrep.2020.107920_bib44","first-page":"1","article-title":"Deaths: final data for 2009","volume":"60","author":"Kochanek","year":"2011","journal-title":"Natl. Vital Stat. Rep."},{"key":"10.1016\/j.celrep.2020.107920_bib45","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/JVI.02308-14","article-title":"Rhabdovirus-based vaccine platforms against henipaviruses","volume":"89","author":"Kurup","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib46","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1128\/JCM.00016-08","article-title":"Lagos bat virus in Kenya","volume":"46","author":"Kuzmin","year":"2008","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.celrep.2020.107920_bib47","doi-asserted-by":"crossref","first-page":"e1002786","DOI":"10.1371\/journal.ppat.1002786","article-title":"Molecular inferences suggest multiple host shifts of rabies viruses from bats to mesocarnivores in Arizona during 2001-2009","volume":"8","author":"Kuzmin","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.celrep.2020.107920_bib48","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/0042-6822(91)90145-2","article-title":"Spread of the CVS strain of rabies virus and of the avirulent mutant AvO1 along the olfactory pathways of the mouse after intranasal inoculation","volume":"183","author":"Lafay","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.celrep.2020.107920_bib49","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/13550280590900427","article-title":"Rabies virus receptors","volume":"11","author":"Lafon","year":"2005","journal-title":"J.\u00a0Neurovirol."},{"key":"10.1016\/j.celrep.2020.107920_bib50","doi-asserted-by":"crossref","first-page":"10756","DOI":"10.1128\/JVI.76.21.10756-10765.2002","article-title":"Mutations Conferring Resistance to Neutralization by a Soluble Form of the Neurotrophin Receptor (p75NTR) Map outside of the Known Antigenic Sites of the Rabies Virus Glycoprotein","volume":"76","author":"Langevin","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jviromet.2013.03.020","article-title":"Evaluation of a non-invasive, inhalational challenge method for rabies vaccine potency assay","volume":"190","author":"Lewis","year":"2013","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.celrep.2020.107920_bib52","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1128\/JCM.01565-13","article-title":"Evaluation of rabies biologics against Irkut virus isolated in China","volume":"51","author":"Liu","year":"2013","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.celrep.2020.107920_bib53","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13567-014-0077-8","article-title":"Twenty year experience of the oral rabies vaccine SAG2 in wildlife: a global review","volume":"45","author":"M\u00e4hl","year":"2014","journal-title":"Vet. Res. (Faisalabad)"},{"key":"10.1016\/j.celrep.2020.107920_bib54","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3201\/eid1301.060810","article-title":"Rabies encephalitis in malaria-endemic area, Malawi, Africa","volume":"13","author":"Mallewa","year":"2007","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.celrep.2020.107920_bib55","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4269\/ajtmh.18-0711","article-title":"Case Reports: Survival from rabies: Case series from India","volume":"100","author":"Mani","year":"2019","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.celrep.2020.107920_bib56","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1128\/JVI.79.8.4672-4678.2005","article-title":"Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis","volume":"79","author":"Marissen","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib57","doi-asserted-by":"crossref","first-page":"385","DOI":"10.20506\/rst.37.2.2809","article-title":"Bat lyssaviruses","volume":"37","author":"Markotter","year":"2018","journal-title":"Rev. Sci. Tech."},{"key":"10.1016\/j.celrep.2020.107920_bib58","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3201\/eid1804.111553","article-title":"Ikoma lyssavirus, highly divergent novel lyssavirus in an African civet","volume":"18","author":"Marston","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.celrep.2020.107920_bib59","doi-asserted-by":"crossref","first-page":"8724","DOI":"10.1128\/JVI.75.18.8724-8732.2001","article-title":"Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector","volume":"75","author":"McGettigan","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib60","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1128\/JVI.77.1.237-244.2003","article-title":"Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic","volume":"77","author":"McGettigan","year":"2003","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib61","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1128\/JVI.75.23.11496-11502.2001","article-title":"Extensive attenuation of rabies virus by simultaneously modifying the dynein light chain binding site in the P protein and replacing Arg333 in the G protein","volume":"75","author":"Mebatsion","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib62","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1128\/jvi.69.3.1444-1451.1995","article-title":"Mokola virus glycoprotein and chimeric proteins can replace rabies virus glycoprotein in the rescue of infectious defective rabies virus particles","volume":"69","author":"Mebatsion","year":"1995","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib63","doi-asserted-by":"crossref","first-page":"e0160553","DOI":"10.1371\/journal.pone.0160553","article-title":"Serological Evidence of Lyssaviruses among Bats on Southwestern Indian Ocean Islands","volume":"11","author":"M\u00e9lade","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.celrep.2020.107920_bib64","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1128\/JVI.73.1.510-518.1999","article-title":"Pathogenicity of different rabies virus variants inversely correlates with apoptosis and rabies virus glycoprotein expression in infected primary neuron cultures","volume":"73","author":"Morimoto","year":"1999","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib65","series-title":"Proceedings of the Southern and Eastern African Rabies Group \/ World Health Organization Meeting","first-page":"80","article-title":"Mokola virus: A brief review of the status quo","author":"Nel","year":"2001"},{"key":"10.1016\/j.celrep.2020.107920_bib66","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1023\/A:1008120511752","article-title":"New cases of Mokola virus infection in South Africa: a genotypic comparison of Southern African virus isolates","volume":"20","author":"Nel","year":"2000","journal-title":"Virus Genes"},{"key":"10.1016\/j.celrep.2020.107920_bib67","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1348-0421.1995.tb03258.x","article-title":"Mapping and characterization of a sequential epitope on the rabies virus glycoprotein which is recognized by a neutralizing monoclonal antibody, RG719","volume":"39","author":"Ni","year":"1995","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.celrep.2020.107920_bib68","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/tbed.12833","article-title":"Tentative novel lyssavirus in a bat in Finland","volume":"65","author":"Nokireki","year":"2018","journal-title":"Transbound. Emerg. Dis."},{"key":"10.1016\/j.celrep.2020.107920_bib69","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/v12030271","article-title":"Serological Survey of Lyssaviruses in Polish Bats in the Frame of Passive Rabies Surveillance Using an Enzyme-Linked Immunosorbent Assay","volume":"12","author":"Or\u0142owska","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.celrep.2020.107920_bib70","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1016\/j.vaccine.2013.09.038","article-title":"Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: implication for post-exposure treatment","volume":"31","author":"Papaneri","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2020.107920_bib71","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1016\/j.vaccine.2015.07.025","article-title":"Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques","volume":"33","author":"Patton","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2020.107920_bib72","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/030098587301000607","article-title":"Experimental infection of dogs and monkeys with two rabies serogroup viruses, Lagos bat and Mokola (IbAn 27377). Gross pathologic and histopathologic changes","volume":"10","author":"Percy","year":"1973","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.celrep.2020.107920_bib73","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0923-2516(96)82287-4","article-title":"The antigen-specific cell-mediated immune response in mice is suppressed by infection with pathogenic Lyssoviruses","volume":"147","author":"Perrin","year":"1996","journal-title":"Res. Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/jvi.62.1.1-7.1988","article-title":"Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence","volume":"62","author":"Prehaud","year":"1988","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib75","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1135710","article-title":"Structure of the Prefusion Form of vesicular stomatitis virus glycoprotein G","volume":"315","author":"Roche","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.celrep.2020.107920_bib76","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jviromet.2011.01.019","article-title":"A non-invasive intranasal inoculation technique using isoflurane anesthesia to infect the brain of mice with rabies virus","volume":"173","author":"Rosseels","year":"2011","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.celrep.2020.107920_bib77","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3201\/eid1309.070466","article-title":"Mokola virus in domestic mammals, South Africa","volume":"13","author":"Sabeta","year":"2007","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.celrep.2020.107920_bib78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1574-695X.2009.00609.x","article-title":"Mokola virus involved in a human contact (South Africa)","volume":"58","author":"Sabeta","year":"2010","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"10.1016\/j.celrep.2020.107920_bib79","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.celrep.2020.107920_bib80","doi-asserted-by":"crossref","first-page":"10690","DOI":"10.1016\/S0021-9258(19)50073-4","article-title":"N-linked glycosylation of rabies virus glycoprotein. Individual sequons differ in their glycosylation efficiencies and influence on cell surface expression","volume":"267","author":"Shakin-Eshleman","year":"1992","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.celrep.2020.107920_bib81","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1128\/jvi.6.5.690-692.1970","article-title":"Two African viruses serologically and morphologically related to rabies virus","volume":"6","author":"Shope","year":"1970","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib82","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1016\/j.vaccine.2017.09.027","article-title":"Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel\u00ae in European and African adults: A phase 1a\/1b, randomized, double-blind multi-centre trial","volume":"35","author":"Sirima","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2020.107920_bib83","first-page":"24","article-title":"Comparison of a Micro-Neutralization Test with the Rapid Fluorescent Focus Inhibition Test for Measuring Rabies Virus Neutralizing Antibodies","volume":"2","author":"Smith","year":"2017","journal-title":"Trop. Med. Infect. Dis."},{"key":"10.1016\/j.celrep.2020.107920_bib84","doi-asserted-by":"crossref","first-page":"20140950","DOI":"10.1098\/rsif.2014.0950","article-title":"Global rise in human infectious disease outbreaks","volume":"11","author":"Smith","year":"2014","journal-title":"J.\u00a0R. Soc. Interface"},{"key":"10.1016\/j.celrep.2020.107920_bib85","first-page":"25","article-title":"Lagos Bat Virus Infection Dynamics in Free-Ranging Straw-Colored Fruit Bats (Eidolon helvum)","volume":"2","author":"Suu-Ire","year":"2017","journal-title":"Trop. Med. Infect. Dis."},{"key":"10.1016\/j.celrep.2020.107920_bib86","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/zph.12352","article-title":"Barriers to innovation in human rabies prophylaxis and treatment: A causal analysis of insights from key opinion leaders and literature","volume":"64","author":"van de Burgwal","year":"2017","journal-title":"Zoonoses Public Health"},{"key":"10.1016\/j.celrep.2020.107920_bib87","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4102\/jsava.v69i4.847","article-title":"Mokola virus infection: description of recent South African cases and a review of the virus epidemiology","volume":"69","author":"von Teichman","year":"1998","journal-title":"J.\u00a0S. Afr. Vet. Assoc."},{"key":"10.1016\/j.celrep.2020.107920_bib88","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1016\/j.vaccine.2016.08.013","article-title":"Vaccine-induced rabies case in a cow (Bos taurus): Molecular characterisation of vaccine strain in brain tissue","volume":"34","author":"Vuta","year":"2016","journal-title":"Vaccine"},{"issue":"W1","key":"10.1016\/j.celrep.2020.107920_bib89","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: homology modelling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.celrep.2020.107920_bib90","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.bbrc.2010.04.133","article-title":"Design and evaluation of a multi-epitope peptide against Japanese encephalitis virus infection in BALB\/c mice","volume":"396","author":"Wei","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.celrep.2020.107920_bib91","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cmi.2015.04.011","article-title":"The neglected zoonoses\u2014the case for integrated control and advocacy","volume":"21","author":"Welburn","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.celrep.2020.107920_bib92","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1017\/S0950268807008965","article-title":"Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes","volume":"136","author":"Weyer","year":"2008","journal-title":"Epidemiol. Infect."},{"issue":"Suppl 2","key":"10.1016\/j.celrep.2020.107920_bib93","doi-asserted-by":"crossref","first-page":"S414","DOI":"10.1093\/infdis\/jiv251","article-title":"Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses","volume":"212","author":"Willet","year":"2015","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.celrep.2020.107920_bib94","doi-asserted-by":"crossref","first-page":"9730","DOI":"10.1128\/JVI.00889-08","article-title":"PPEY motif within the rabies virus (RV) matrix protein is essential for efficient virion release and RV pathogenicity","volume":"82","author":"Wirblich","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2020.107920_bib95","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/glycob\/8.2.121","article-title":"The role of site-specific N-glycosylation in secretion of soluble forms of rabies virus glycoprotein","volume":"8","author":"Wojczyk","year":"1998","journal-title":"Glycobiology"},{"key":"10.1016\/j.celrep.2020.107920_bib96","first-page":"77","article-title":"Human rabies: 2016 updates and call for data","volume":"92","year":"2017","journal-title":"Wkly. Epidemiol. Rec."},{"key":"10.1016\/j.celrep.2020.107920_bib97","series-title":"The Immunological Basis for Immunization Series: Module 17: Rabies Vaccines","year":"2017"},{"key":"10.1016\/j.celrep.2020.107920_bib98","series-title":"Laboratory Techniques in Rabies","year":"2018"},{"key":"10.1016\/j.celrep.2020.107920_bib99","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.virol.2010.09.014","article-title":"Virus neutralising activity of African fruit bat (Eidolon helvum) sera against emerging lyssaviruses","volume":"408","author":"Wright","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.celrep.2020.107920_bib100","series-title":"Rabies: Scientific Basis of the Disease and Its Management","author":"Wunner","year":"2010"},{"key":"10.1016\/j.celrep.2020.107920_bib101","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1128\/CVI.00066-11","article-title":"Evaluation of a novel chimeric B cell epitope-based vaccine against mastitis induced by either Streptococcus agalactiae or Staphylococcus aureus in mice","volume":"18","author":"Xu","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.celrep.2020.107920_bib102","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.chom.2019.12.012","article-title":"Structural Analysis of Rabies Virus Glycoprotein Reveals pH-Dependent Conformational Changes and Interactions with a Neutralizing Antibody","volume":"27","author":"Yang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.celrep.2020.107920_bib103","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2105-9-40","article-title":"I-TASSER server for protein 3D structure prediction","volume":"9","author":"Zhang","year":"2008","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.celrep.2020.107920_bib104","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1016\/j.vaccine.2009.05.009","article-title":"Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB\/c mice model","volume":"27","author":"Zhou","year":"2009","journal-title":"Vaccine"}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124720309013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124720309013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:38:35Z","timestamp":1778841515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124720309013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":104,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S2211124720309013"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2020.107920","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2020.107920","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"107920"}}